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Abstract 
Background: Hydroxychloroquine sulphate (HCQ) is being scrutinized for 
repositioning in the treatment and prevention of SARS-Cov-2 infection. This 
 
 











antimalarial drug is also chronically used to treat patients with autoimmune 
diseases. 
Methods: By analysing the Portuguese anonymized data on private and 
public based medical prescriptions we have identified all cases chronically 
receiving HCQ for the management of diseases such as systemic lupus 
erythematosus, rheumatoid arthritis, and other autoimmune diseases. 
Additionally, we have detected all laboratory confirmed cases of SARS-
CoV-2 infection and all laboratory confirmed negative cases in the 
Portuguese population (mandatorily registered in a centrally managed 
database). Cross linking the two sets of data has allowed us to compare the 
proportion of HCQ chronic treatment (at least 2 grams per month) in 
laboratory confirmed cases of SARS-CoV-2 infection with laboratory 
confirmed negative cases. 
Results: Out of 26,815 SARS-CoV-2 positive patients, 77 (0.29%) were 
chronically treated with HCQ, while 1,215 (0.36%) out of 333,489 negative 
patients were receiving it chronically (P=0.04). After adjustment for age, 
sex, and chronic treatment with corticosteroids and/or 
immunosuppressants, the odds ratio of SARS-CoV-2 infection for chronic 
treatment with HCQ has been 0.51 (0.37-0.70). 
Conclusions: Our data suggest that chronic treatment with HCQ confer 

















Several in vitro studies have shown chloroquine phosphate and 
hydroxychloroquine sulphate (HCQ) to be effective in both preventing and 
treating SARS-CoV-2 infection in isolated cells (1-3). Chloroquine 
phosphate and HCQ were also found effective in the treatment of COVID-
19 patients in small nonrandomized or unblinded clinical studies (4-6). A 
recent observational study has shown no association between HCQ use 
and the composite endpoint of intubation or death in hospitalized patients 
(7). However, up until today there are no available results from well 
designed, randomized, double blinded, placebo controlled clinical trials 
showing any evidence of a therapeutic or preventive effect of these drugs in 
SARS-CoV-2 infection. 
These two drugs are also chronically used to treat systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA) and other autoimmune 
diseases. SLE patients are at increased risk of viral infections (8). 
Increased ratios of serious bacterial and viral infections have been shown 
or are expected in different autoimmune diseases (8-11). Thus, patients 
with these diseases should be expected to have increased ratios of SARS-
CoV-2 infection as compared to the general population. Antimalarials 


















To evaluate the effect of chronic treatment with HCQ for other medical 
conditions in SARS-COV-2 infection incidence. 
Patients and methods 
Data collection 
The Portuguese National Health Service (Serviço Nacional de Saúde – 
SNS) has a centrally controlled electronic database where all drug 
prescriptions, both from public and private medical care, are systematically 
registered (Prescrição Electrónica de Medicamentos – PEM, Serviços 
Partilhados do Ministério da Saúde – SPMS). In Portugal, all prescriptions 
are mandatorily made through a personal computer platform (there are no 
prescriptions on paper), in both public and private health services and are 
recorded in that centralized database. 
A specific database allows the registry of obligatory notifiable diseases, 
including the suspected and confirmed cases of SARS-CoV-2 infection 
(Sistema Nacional de Vigilância Epidemiológica – SINAVE MED, Direcção 
Geral da Saúde – DGS). Another database allows the registry of all 
polymerase chain reaction (PCR) tests for SARS-CoV-2 performed in the 
country (SINAVE LAB, DGS). 
Anonymized data were extracted from these databases. By analysing these 
sets of data, we were able to detect all patients with SARS-CoV-2 
confirmed infections and all clinically suspected but non-confirmed patients 
 
 











between Mars 2, 2020 (the date of the first Portuguese case) and the 
moment of the analysis. All cases prescribed with HCQ between January 1, 
2019 and December 31, 2019 for other medical conditions were 
documented too. Additionally, we identified all prescriptions of 
corticosteroids (prednisolone, methylprednisolone, dexamethasone and 
deflazacort) and/or immunosuppressants (cyclophosphamide, azathioprine, 
cyclosporine, methotrexate, or mycophenolate mofetil) in the same period. 
Case definitions 
Suspected case: patient with acute respiratory infection (sudden onset of 
fever or cough or respiratory distress) with no other aetiology explaining the 
condition and with a history of travel or residence in areas with active 
community transmission of SARS-CoV-2 within 14 days prior to onset of 
symptoms; or patient with acute respiratory infection and a history of 
contact with a confirmed or likely case of infection with SARS-CoV-2 or 
CoVID-19 within 14 days prior to the onset of symptoms; or patient with 
severe acute respiratory infection, requiring hospitalization with no other 
aetiology. 
Confirmed case: patient with laboratory confirmation of SARS-CoV-2 
infection by nasopharynx swab PCR test, regardless of signs and 
symptoms. 
Since there were many unidentified records in SINAVE LAB (including 
expatriates), all cases in which at least one positive PCR test could be 
detected in the laboratory database were considered positive; all the other 
 
 











cases were checked against the SINAVE MED database and considered 
positive if registered as a confirmed case in this database (according to 
case definition) or negative otherwise. 
To be considered under chronic treatment with HCQ, cases had to be 
prescribed with at least 2 grams of HCQ per month, on average. 
Chloroquine phosphate is not available in Portugal. 
Patients with, at least, 6 months on corticosteroids and/or 
immunosuppressants were considered under chronic immunosuppressant 
treatment. 
For each case, the first 2019 HCQ prescription was identified (index 
prescription). Then, the total HCQ dose (in grams) prescribed from the 
index prescription (inclusive) was quantified up until the last day of 2019. 
Finally, the average monthly dose of HCQ was computed. The same 
methodology was used for corticosteroids and immunosuppressants, but 
the number of prescriptions (not grams) was quantified. 
Non-residents in Portugal were excluded from the study. 
Data Extraction 
Anonymized raw data were extracted from the abovementioned databases 
on June 2, 2020. The raw data were revised to ensure internal consistency 
and transformed into a structured database for analysis. 
The SINAVE LAB database had the registry of 679,265 PCR tests 
conducted in Portugal up to the moment of the extraction. Of these, 
 
 











189,734 were not identifiable and were excluded from the analysis. 
However, by cross-referencing the information from SINAVE LAB with 
SINAVE MED, it was possible to identify 360,552 suspected cases of 
SARS-CoV-2 infection. 
The extraction from PEM database had the registry of 26.735 patients who 
were prescribed the study medications between January 1, 2019 and 
December 31, 2019, including the number of prescriptions and their dates. 
Data analysis 
We have analysed the prevalence of HCQ chronic treatment in all PCR 
tested patients, comparing PCR positive cases with PCR negative cases. 
Statistical analysis 
Numeric variables are presented as mean ± standard deviation. Proportions 
are presented as percentages. 
Student’s t-test was used to test for differences between numeric variables. 
The chi-square test was used to test for differences between categorical 
variables. 
Logistic regression was used to adjust the effect of the independent 


















This study was approved by the Ethics Review Board of Centro Hospitalar 
Universitário de São João and Faculdade de Medicina da Universidade do 
Porto. 
Results 
The first case of SARS-CoV-2 infection in Portugal was recorded on 2 
March 2020. Since then, until the moment we analysed the data, 360,304 
patients with suspected SARS-CoV-2 infection had a final case definition 
(positive PCR test or negative PCR test). In 248 cases the PCR test result 
was inconclusive and had not yet been repeated at the time of data 
extraction. Of these 360,304 cases, 26,815 were confirmed by a positive 
PCR test. The rest had negative PCR tests. 
In the set of patients with case definition, 1,292 received HCQ (at least 2 
grams per month) and 897 were prescribed with corticosteroids and/or 
immunosuppressants for 6 months at least. 
Univariate analysis 
The results of univariate analysis are summarized in table 1. SARS-CoV-2 
positive patients were older and more often of the male gender than 
negative patients. 
The proportion of HCQ chronic treatment was higher in negative patients 
(0.36% vs. 0.29%, P = 0.04) and the inverse was true for corticosteroids 
and/or immunosuppressants chronic treatment (0.24% vs. 0.31%, P = 
 
 











0.05). The unadjusted odds ratio of a positive test for HCQ chronic 
treatment was 0.79 (0.63-0.99). 
The incidence of SARS-CoV-2 infection in patients receiving HCQ was 
5.96%, while in the other patients it was 7.45% 
Multivariate analysis 
As shown in table 2, after adjustment for demographic characteristics and 
immunosuppressive treatment, HCQ remained independently and 
negatively associated with SARS-CoV-2 infection. The adjusted odds ratio 
of a positive PCR test for HCQ chronic treatment was 0.51 (0.37-0.70). 
Immunosuppressive treatment was found to be positively associated with 
SARS-CoV-2 infection with an odds ratio of 2.06 (1.51-2.82). 
Discussion 
As far as we know, this is the first study retrospectively assessing the 
relationship between chronic treatment with HCQ and SARS-CoV-2 
infection in a large sample of patients at a nation-while level. 
In this study, we only included patients chronically prescribed with HCQ 
during 2019, whose prescriptions continued into 2020. This way, we were 
able to exclude those who have started taking HCQ aiming to treat or 
prevent SARS-CoV-2 infection. Otherwise, this would be a confounding 
factor in the analysis of the data. 
Although we have no information on comorbidities of the patients registered 
in the databases used in this study, it seems fair to assume that patients 
 
 











who chronically received HCQ at a dose of at least 2 grams per month have 
SLE, RA or other autoimmune diseases. In fact, in Portugal, HCQ is 
approved for the treatment of SLE, discoid lupus erythematosus, RA, 
juvenile idiopathic arthritis, and for the prophylaxis and treatment of malaria, 
which is not endemic (only imported cases). In the last case, the dose and 
duration of the treatment are much lower than the ones selected for 
inclusion in this study. Thus, patients using HCQ for prophylaxis or 
treatment of malaria were excluded from the study by the inclusion criteria 
we have used. The prevalence of SLE and RA in Portugal is 0.1% and 
0.7%, respectively (13). These figures have allowed us to assume that 
chronic treatment with HCQ in such doses is a surrogate indicator of an 
autoimmune disease diagnosis. 
Patients with SLE or RA have numerous cellular and humoral abnormalities 
that contribute to an increased susceptibility to infectious agents (14-16). 
SLE patients have a 3.9 times higher incidence rate of severe herpes 
simplex virus infection than controls (9). SLE patients treated with 
glucocorticoids alone also have a 3.9-fold hazard ratio for severe infections 
when compared to patients treated with HCQ alone (11). The prevalence of 
papillomavirus and cytomegalovirus is supposedly higher in patients with 
autoimmune diseases too (9,10). Besides the negative effect of the 
immunologic disturbance, these patients usually receive 















Thus, the available data suggest that autoimmune patients are at increased 
risk of viral infections. The benefits of HCQ treatment in this context, if any, 
depend on its ability to prevent those infections. The COVID-19 risk scoring 
guide of the British Society for Rheumatology (17) seems to adopt the 
same orientation, by scoring with zero the use of HCQ while it scores with 
three high-dose corticosteroids and cyclophosphamide. Our data give 
further support to this suggestion. 
We were able to show that patients taking HCQ have had reduced odds of 
SARS-CoV-2 infection. This effect was most evident after adjustment for 
age, sex, and chronic immunosuppressive treatment, increasing the 
likelihood that chronic treatment with HCQ actually has a protective effect 
against SARS-CoV-2 infection. 
A recent paper compared the proportions of HCQ use in SARS-CoV-2 
positive and negative patients (18), finding no differences between the two 
groups. However, as study limitation, the authors stated that the duration of 
treatment was not documented and only 3 patients received HCQ in the 
positive cases group. An Indian study showed that HCQ (in the dosage 
currently used in the prophylaxis of malaria and after four maintenance 
doses) was effective in preventing SARS-CoV-2 infection in health care 
workers (19), while another paper showed no statistically significant effect 
of HCQ (in the dose of 600 mg/day for four days, after a loading dose of 
800 mg plus 600 mg after 6 to 8 hours) in postexposure prevention (20). 
The first two studies evaluated the effectiveness of HCQ as pre-exposure 
prophylaxis, while the latter assessed its effectiveness as post-exposure 
 
 











prophylaxis. Taken together, these results suggest that an extended period 
of HCQ treatment may be necessary in patients without prior contact with 
the virus to obtain a preventive effect. We believe our data supports this 
hypothesis. 
Available data show that there was a significant increase of HCQ 
prescriptions in March 2020 and in the first two weeks of April 2020. 
Additional studies are needed to understand whether this increase in HCQ 
consumption has had any effect on the evolution of the outbreak in Portugal 
and on the incidence of adverse events. 
In conclusion, our findings suggest that HCQ might have a preventive effect 
of SARS-CoV-2 infection. 
Statistical limitations 
Despite having a considerable number of lab tests that were missing in the 
official electronic registries, we believe that we have captured all suspected 
confirmed and unconfirmed cases of SARS-CoV-2 infection by checking the 
lab data (SINAVE LAB) against de the obligatory registry database 
(SINAVE MED). Furthermore, all positive and negative cases included in 
our sample were confirmed by PCR testing, giving consistency to our 
results. 
The fact that we do not have information on comorbidities may be a major 
limitation of the study, because it did not allow us to exclude a potential 
selection bias – for example, physicians may have decided to prescribe 
HCQ to patients with fewer comorbidities, and because it was not possible 
 
 











to adjust the effect of HCQ to such comorbidities. Thus, the observed effect 
could be related to a better health status of patients and not to a preventive 
action of HCQ. However, clinical guidelines recommend the use of 
antimalarials in all cases (21), regardless of the existence of comorbidities 
(namely, those that may affect resistance to infection, such as chronic renal 
failure). It is therefore to be expected that physicians have followed those 
recommendations and that no such selection bias has occurred. 
We do not have any data on the therapeutic compliance of patients, and 
this is a study limitation too. 
Although the proportions of HCQ chronic treatment are low, the difference 
in proportions between the two groups is unlikely to be cancelled out by the 
study pitfalls mentioned above. 
Study implications 
Considering the low toxicity (22-24) and the enormous clinical experience 
with HCQ utilization, these results strongly suggest it should continue to be 
used in patients with autoimmune diseases, mostly in the context of the 
SARS-CoV-2 pandemic. Whether it should be used as a pre-exposure 
prophylactic measure in other risk groups or in the general population is 
unknown. Despite concerns about the safety of HCQ when used in patients 
hospitalized with Covid-19 (25), namely because of QTc interval 
prolongation, we believe that our findings suggest that at least it should be 
considered for this purpose. The lockdown is severely affecting the world’s 
economy, increasing unemployment, and inducing more suffering than the 
 
 











disease itself. Eventually, its effects on the welfare of the populations will be 
much worse than the potential adverse effects of HCQ prophylaxis. 
Furthermore, it cannot be maintained for an extended period. Thus, while 
waiting for an effective and safe vaccine, a chemoprophylaxis-based 
strategy, using this inexpensive drug, continuously monitored (because of 
potential side effects) and modified according to the results of ongoing 
clinical trials, may be justified. 
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Table 1: Demographic characteristics, HCQ and corticosteroid and/or 
immunosuppressive treatment in SARS-CoV-2 positive and negative cases 








 n = 26,815 n = 
333,489 
 
HCQ 77 (0.29%) 1,215 
(0.36%) 
0.04 





Age (years) 52.2±22.4 50.8±22.4 <0.0001 
 
 











CCT/Immunos. 82 (0.31%) 81 (0.24%) 0.05 
CCT – corticosteroids; Immunos. – immunosuppressants (treatment with 
corticosteroids – prednisolone, methylprednisolone, deflazacort or 
dexamethasone, and/or immunosuppressants – cyclophosphamide, 
cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil for at 
least 6 months). 
HCQ – at least 2 grams per month, on average. 
Age was missing in 776 cases (2 positives and 774 negatives). Gender was 
missing in 822 cases (1 positive and 821 negatives). The results exclude 
missing data. 
Table 2: Odds ratios (and 95% CI) of SARS-CoV-2 infection for study 
variables in multivariate analysis (logistic regression) 
Dependent variable: SARS-CoV-2 positive PCR test. 
Independent variables: 
 OR 95%CI 
HCQ 0.51 0.37-0.70 
Male gender 1.11 1.09-1.14 
 
 














CCT/Immunos. 2.06 1.51-2.82 
CCT – corticosteroids; Immunos. – immunosuppressants (treatment with 
corticosteroids – prednisolone, methylprednisolone, deflazacort or 
dexamethasone and/or immunosuppressants – cyclophosphamide, 
cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil for at 
least 6 months). 
HCQ – at least 2 grams per month, on average. 
The logistic regression model included 359,476 cases (positive cases – 
26,813; negative cases – 332,663) due to missing data. 
 
